Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Paradoxical Responses to Zolpidem
2023-507404-31-03Phase 2Suspended
- Sponsor
- University of Liège
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of zolpidem in disorder of consciousness (DOC), eye abnormalities and vision loss (2 arms), sponsored by University of Liège. Primary endpoints: Consciousness level in DoC patients, Neural complexity in DoC patients and 10 more. Started Jan 2025; status: suspended.
02
Drugs
zolpidem
03
Conditions
disorder of consciousness (DOC)eye abnormalitiesvision loss
Beyond the preview
Go deeper on 2023-507404-31-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507404-31-03.